NOXCOVID-1 began recruiting patients two weeks ago, on 30 September, according to an update on clinicaltrials.com
As treatment lasts just 14 days, a formal review of the first (400 mg) cohort should be completed by the end of October. Safety will of course be critical, but it would be wonderful if we also saw evidence of efficacy.
As this is a dose-escalation trial, my guess is that Noxopharm will update the market whenever a new dose level is cleared to start, so we are likely to see a series of announcements in a short period.
If results disappoint, we still have DARRT-2 and IONIC to look forward to in early 2021. If results are good, this will be the last chance to buy NOX at these prices, in my opinion.
Add to My Watchlist
What is My Watchlist?
